Evidence map›Paper›PMID 42702917›Full record

ArticleRisk analysis : an official publication of the Society for Risk Analysis2026

Risk Calibration: Divergent Interpretations of Risk Assessment in Norway's Early COVID-19 Response.

André R Karlsen

Abstract read
In one paragraph

Article in Risk analysis : an official publication of the Society for Risk Analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

André R KarlsenNTNU Samfunnsforskning AS, Trondheim, Norway.ORCID https://orcid.org/0000-0003-3253-0308

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

During the early phases of novel disease outbreaks, risk management must rely largely on non-pharmaceutical interventions, since consensus-based biomedical solutions are yet to be developed. This paper examines how and why expert organizations arrive at divergent interpretations of the same risk assessments, and what such divergence means for risk management strategies. Using Norway's early COVID-19 response as a qualitative case, the study analyzes the disagreement between national health authorities over suppression versus mitigation strategies. Data consist of interviews with key decision-makers and senior analysts, supplemented by extensive interview material and reports from the Norwegian Corona Commission, and are analyzed using thematic analysis. The findings show that the disagreement did not primarily stem from different estimates of epidemiological risk, but from divergent interpretations of what those estimates implied: where the main consequences of the pandemic would concentrate, and whether existing health-system capacities could control the situation. To explain this, the paper introduces the concepts of (1) risk epicenter, where the risk is interpreted to concentrate and (2) risk controllability, the assessed institutional capacity to control it. Together, these constitute a process termed risk calibration, through which technical risk assessments are socially and institutionally interpreted. The contribution is a two-dimensional framework for analyzing the structure of divergent interpretations during the early phase of novel risk events. The study argues that incorporating both dimensions into early-phase risk analysis is essential for understanding policy disagreement and improving preparedness for future large-scale, novel risks.

Indexed as

COVID-19PandemicsCalibrationHumansNorwayRisk AssessmentRisk ManagementSARS-CoV-2

Identifiers

PMID42702917
PMCPMC13547759

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.